These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23936455)

  • 1. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
    Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
    PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
    Ruzzo A; Graziano F; Vincenzi B; Canestrari E; Perrone G; Galluccio N; Catalano V; Loupakis F; Rabitti C; Santini D; Tonini G; Fiorentini G; Rossi D; Falcone A; Magnani M
    Oncologist; 2012; 17(6):823-9. PubMed ID: 22584434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN.
    Wang XR; Luo H; Li HL; Cao L; Wang XF; Yan W; Wang YY; Zhang JX; Jiang T; Kang CS; Liu N; You YP;
    Neuro Oncol; 2013 Nov; 15(11):1491-501. PubMed ID: 24092860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K-Ras and HMGA2 gene expression.
    Wang YY; Ren T; Cai YY; He XY
    Cancer Biother Radiopharm; 2013 Mar; 28(2):131-7. PubMed ID: 23134218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
    Duldulao MP; Lee W; Nelson RA; Li W; Chen Z; Kim J; Garcia-Aguilar J
    Ann Surg Oncol; 2013 Jul; 20(7):2166-71. PubMed ID: 23456389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.
    Crowley EH; Arena S; Lamba S; Di Nicolantonio F; Bardelli A
    Hum Mutat; 2014 Feb; 35(2):208-14. PubMed ID: 24282149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.
    De Bruijn MT; Raats DA; Tol J; Hinrichs J; Teerenstra S; Punt CJ; Rinkes IH; Kranenburg O
    Anticancer Res; 2011 Apr; 31(4):1379-85. PubMed ID: 21508389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
    Amankwatia EB; Chakravarty P; Carey FA; Weidlich S; Steele RJ; Munro AJ; Wolf CR; Smith G
    Br J Cancer; 2015 Apr; 112(9):1480-90. PubMed ID: 25919696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Let-7a regulates mammosphere formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in breast cancer stem cells.
    Xu C; Sun X; Qin S; Wang H; Zheng Z; Xu S; Luo G; Liu P; Liu J; Du N; Zhang Y; Liu D; Ren H
    Cell Cycle; 2015; 14(11):1686-97. PubMed ID: 25955298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ER-, PR-, AR+ breast cancer.
    Lyu S; Yu Q; Ying G; Wang S; Wang Y; Zhang J; Niu Y
    Int J Oncol; 2014 Jan; 44(1):229-37. PubMed ID: 24172884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.
    Pan XM; Sun RF; Li ZH; Guo XM; Zhang Z; Qin HJ; Xu GH; Gao LB
    Tumour Biol; 2014 Jan; 35(1):831-5. PubMed ID: 23975373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
    Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
    Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of apoptosis-related interactions in colorectal cancer.
    Arora H; Qureshi R; Rizvi MA; Shrivastava S; Parihar MS
    Tumour Biol; 2016 Nov; 37(11):14415-14425. PubMed ID: 27629291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
    Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
    Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.
    Oden-Gangloff A; Di Fiore F; Bibeau F; Lamy A; Bougeard G; Charbonnier F; Blanchard F; Tougeron D; Ychou M; Boissière F; Le Pessot F; Sabourin JC; Tuech JJ; Michel P; Frebourg T
    Br J Cancer; 2009 Apr; 100(8):1330-5. PubMed ID: 19367287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment.
    Licar A; Cerkovnik P; Ocvirk J; Novakovic S
    Int J Oncol; 2010 May; 36(5):1137-44. PubMed ID: 20372787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
    Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
    Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.
    Valentino JD; Elliott VA; Zaytseva YY; Rychahou PG; Mustain WC; Wang C; Gao T; Evers BM
    Surgery; 2012 Aug; 152(2):277-85. PubMed ID: 22828149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.